Clinical and Laboratory Findings of COVID-19 in High-Altitude Inhabitants of Saudi Arabia
Background: SARS-CoV-2, the causative agent of COVID-19, continues to cause a worldwide pandemic, with more than 147 million being affected globally as of this writing. People's responses to COVID-19 range from asymptomatic to severe, and the disease is sometimes fatal. Its severity is affected by different factors and comorbidities of the infected patients. Living at a high altitude could be another factor that affects the severity of the disease in infected patients.Methods: In the present study, we have analyzed the clinical, laboratory, and radiological findings of COVID-19-infected patients in Taif, a high-altitude region of Saudi Arabia. In addition, we compared matched diseased subjects to those living at sea level. We hypothesized that people living in high-altitude locations are prone to develop a more severe form of COVID-19 than those living at sea level.Results: Age and a high Charlson comorbidity score were associated with increased numbers of intensive care unit (ICU) admissions and mortality among COVID-19 patients. These ICU admissions and fatalities were found mainly in patients with comorbidities. Rates of leukocytosis, neutrophilia, higher D-dimer, ferritin, and highly sensitive C-reactive protein (CRP) were significantly higher in ICU patients. CRP was the most independent of the laboratory biomarkers found to be potential predictors of death. COVID-19 patients who live at higher altitude developed a less severe form of the disease and had a lower mortality rate, in comparison to matched subjects living at sea level.Conclusion: CRP and Charlson comorbidity scores can be considered predictive of disease severity. People living at higher altitudes developed less severe forms of COVID-19 disease than those living at sea level, due to a not-yet-known mechanism..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Frontiers in Medicine - 8(2021) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mostafa Abdelsalam [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
CO-RADS classification |
|---|
| doi: |
10.3389/fmed.2021.670195 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ062499114 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ062499114 | ||
| 003 | DE-627 | ||
| 005 | 20230502140742.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fmed.2021.670195 |2 doi | |
| 035 | |a (DE-627)DOAJ062499114 | ||
| 035 | |a (DE-599)DOAJfbc36f741bb544f0a0075af5e5b42c15 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a R5-920 | |
| 100 | 0 | |a Mostafa Abdelsalam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical and Laboratory Findings of COVID-19 in High-Altitude Inhabitants of Saudi Arabia |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: SARS-CoV-2, the causative agent of COVID-19, continues to cause a worldwide pandemic, with more than 147 million being affected globally as of this writing. People's responses to COVID-19 range from asymptomatic to severe, and the disease is sometimes fatal. Its severity is affected by different factors and comorbidities of the infected patients. Living at a high altitude could be another factor that affects the severity of the disease in infected patients.Methods: In the present study, we have analyzed the clinical, laboratory, and radiological findings of COVID-19-infected patients in Taif, a high-altitude region of Saudi Arabia. In addition, we compared matched diseased subjects to those living at sea level. We hypothesized that people living in high-altitude locations are prone to develop a more severe form of COVID-19 than those living at sea level.Results: Age and a high Charlson comorbidity score were associated with increased numbers of intensive care unit (ICU) admissions and mortality among COVID-19 patients. These ICU admissions and fatalities were found mainly in patients with comorbidities. Rates of leukocytosis, neutrophilia, higher D-dimer, ferritin, and highly sensitive C-reactive protein (CRP) were significantly higher in ICU patients. CRP was the most independent of the laboratory biomarkers found to be potential predictors of death. COVID-19 patients who live at higher altitude developed a less severe form of the disease and had a lower mortality rate, in comparison to matched subjects living at sea level.Conclusion: CRP and Charlson comorbidity scores can be considered predictive of disease severity. People living at higher altitudes developed less severe forms of COVID-19 disease than those living at sea level, due to a not-yet-known mechanism. | ||
| 650 | 4 | |a COVID–19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a high-altitude | |
| 650 | 4 | |a crp | |
| 650 | 4 | |a CO-RADS classification | |
| 650 | 4 | |a d-dimer | |
| 653 | 0 | |a Medicine (General) | |
| 700 | 0 | |a Mostafa Abdelsalam |e verfasserin |4 aut | |
| 700 | 0 | |a Raad M. M. Althaqafi |e verfasserin |4 aut | |
| 700 | 0 | |a Sara A. Assiri |e verfasserin |4 aut | |
| 700 | 0 | |a Taghreed M. Althagafi |e verfasserin |4 aut | |
| 700 | 0 | |a Saleh M. Althagafi |e verfasserin |4 aut | |
| 700 | 0 | |a Ahmed Y. Fouda |e verfasserin |4 aut | |
| 700 | 0 | |a Ahmed Y. Fouda |e verfasserin |4 aut | |
| 700 | 0 | |a Ahmed Ramadan |e verfasserin |4 aut | |
| 700 | 0 | |a Ahmed Ramadan |e verfasserin |4 aut | |
| 700 | 0 | |a Mohammed Rabah |e verfasserin |4 aut | |
| 700 | 0 | |a Mohammed Rabah |e verfasserin |4 aut | |
| 700 | 0 | |a Reham M. Ahmed |e verfasserin |4 aut | |
| 700 | 0 | |a Reham M. Ahmed |e verfasserin |4 aut | |
| 700 | 0 | |a Zein S. Ibrahim |e verfasserin |4 aut | |
| 700 | 0 | |a Dalal M. Nemenqani |e verfasserin |4 aut | |
| 700 | 0 | |a Ahmed N. Alghamdi |e verfasserin |4 aut | |
| 700 | 0 | |a Daifullah Al Aboud |e verfasserin |4 aut | |
| 700 | 0 | |a Ahmed S. Abdel-Moneim |e verfasserin |4 aut | |
| 700 | 0 | |a Adnan A. Alsulaimani |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Medicine |d Frontiers Media S.A., 2014 |g 8(2021) |w (DE-627)DOAJ000022292 |x 2296858X |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2021 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fmed.2021.670195 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/fbc36f741bb544f0a0075af5e5b42c15 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fmed.2021.670195/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2296-858X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2021 | ||